{"filing":{"accession_number":"0001070081-26-000019","cik":"0001070081","ticker":"PTCT","company_name":"PTC THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-25","primary_document":"tmb-20260825x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070081/000107008126000019/tmb-20260825x8k.htm"},"events":[{"id":30300,"run_id":27773,"accession_number":"0001070081-26-000019","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"PTC Therapeutics entered into an asset purchase agreement with Sangamo Therapeutics to acquire ST-920, an AAV gene therapy product candidate for Fabry disease, for $111 million upfront plus up to $100 million in contingent milestone payments. This is a material acquisition of assets disclosed under Item 1.01, involving a significant financial commitment and strategic addition to the company's pipeline. The transaction is subject to Bankruptcy Court approval scheduled for September 10, 2026.","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32859,"accession_number":"0001070081-26-000019","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"PTC Therapeutics entered into an asset purchase agreement with Sangamo Therapeutics to acquire ST-920, an AAV gene therapy product candidate for Fabry disease, for $111 million upfront plus up to $100 million in contingent milestone payments. This is a material acquisition of assets disclosed under Item 1.01, involving a significant financial commitment and strategic addition to the company's pipeline. The transaction is subject to Bankruptcy Court approval scheduled for September 10, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T20:08:35.131751+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32859,"accession_number":"0001070081-26-000019","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"PTC Therapeutics entered into an asset purchase agreement with Sangamo Therapeutics to acquire ST-920, an AAV gene therapy product candidate for Fabry disease, for $111 million upfront plus up to $100 million in contingent milestone payments. This is a material acquisition of assets disclosed under Item 1.01, involving a significant financial commitment and strategic addition to the company's pipeline. The transaction is subject to Bankruptcy Court approval scheduled for September 10, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T20:08:35.131751+00:00","company_name":"PTC THERAPEUTICS, INC.","ticker":"PTCT","filing_date":"2026-08-28"}]}